MARKET

PYPD

PYPD

Polypid Ltd.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.04
+0.04
+0.67%
Closed 16:00 08/12 EDT
OPEN
5.96
PREV CLOSE
6.00
HIGH
6.24
LOW
5.96
VOLUME
12.99K
TURNOVER
67.85K
52 WEEK HIGH
9.64
52 WEEK LOW
3.920
MARKET CAP
117.60M
P/E (TTM)
-2.4318
1D
5D
1M
3M
1Y
5Y
--BMO Capital Adjusts PolyPid's Price Target to $25 from $27, Keeps Outperform Rating
--BMO Capital Adjusts PolyPid's Price Target to $25 from $27, Keeps Outperform Rating
MT Newswires · 1d ago
PolyPid GAAP EPS of -$1.23 misses by $0.60
PolyPid press release (<span class="ticker-hover-wrapp...
Seekingalpha · 2d ago
BRIEF-Polypid reports Q2 results
BRIEF-Polypid reports Q2 results
Reuters · 2d ago
PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Signed Exclusive Licensing Agreement for Commercialization of D-PLEX100 in Europe for Potentially Over $110 Million in Upfront and Milestone Payments, Plus Royalties on Net SalesIndependent Data Safety Monitoring Board Recommended Concluding Phase 3 SHIELD...
GlobeNewswire · 2d ago
PolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in Europe
PolyPid (NASDAQ:PYPD) <a href="https://seekingalpha.com/pr/18889653-...
Seekingalpha · 08/03 13:13
PolyPid Announces Exclusive Licensing Agreement With ADVANZ PHARMA For The Commercialization Of D-PLEX₁₀₀ In Europe; Polypid To Potentially Receive Over $110M In Upfront And Milestone Payments As Well As Royalties On Net Sales
PolyPid Ltd. (NASDAQ:PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has entered into an exclusive licensing
Benzinga · 08/03 11:23
BRIEF-PolyPid Announces Exclusive Licensing Agreement With Advanz Pharma
BRIEF-PolyPid Announces Exclusive Licensing Agreement With Advanz Pharma
Reuters · 08/03 11:20
PolyPid Enters Into Licensing Deal With Advanz Pharma for Surgical Infection Prevention Drug
PolyPid Enters Into Licensing Deal With Advanz Pharma for Surgical Infection Prevention Drug
MT Newswires · 08/03 11:12
More
No Data
Learn about the latest financial forecast of PYPD. Analyze the recent business situations of Polypid Ltd. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

16.67%Strong Buy
83.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PYPD stock price target is 22.29 with a high estimate of 27.00 and a low estimate of 15.00.
High27.00
Average22.29
Low15.00
Current 6.04
EPS
Actual
Estimate
-0.57-0.43-0.28-0.14
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 33
Institutional Holdings: 1.15M
% Owned: 5.92%
Shares Outstanding: 19.47M
TypeInstitutionsShares
Increased
9
197.07K
New
4
53.64K
Decreased
5
410.42K
Sold Out
4
229.81K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.44%
Pharmaceuticals & Medical Research
+1.45%
Key Executives
Non-Executive Chairman/Independent Director
Jacob Harel
Chief Executive Officer/Director
Amir Weisberg
Chief Financial Officer/Executive Vice President
Dikla Akselbrad
Chief Operating Officer/Executive Vice President
Shaul Mukhtar
Senior Vice President
Dalit Hazan
Chief Scientific Officer
Noam Emanuel
Other
Ori Warshavsky
Independent Director
Yechezkel Barenholz
Independent Director
Nir Dror
Independent Director
Chaim Hurvitz
Independent Director
Itzhak Krinsky
Independent Director
Anat Segal
Independent Director
Robert Stein
No Data
No Data
About PYPD
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Webull offers kinds of Polypid Ltd stock information, including NASDAQ:PYPD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PYPD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PYPD stock methods without spending real money on the virtual paper trading platform.